You are here: Home » Companies » News
Business Standard

CCI approves deal to acquire minority stake in BDR Pharmaceuticals

BDR Pharmaceuticals is mainly into four therapeutic segments -- oncology, critical care, gynaecology, and neurology

Topics
pharmaceutical firms | Competition Commission of India | CCI

Press Trust of India  |  New Delhi 

Photo: PTI
Photo: PTI

The Competition Commission has cleared the proposed acquisition of a minority stake in BDR Pharmaceuticals International Pvt Ltd by Multiples Private Equity Fund III and other investors.

Under the transaction, the minority stake would be purchased by Multiples Private Equity Fund III, SRF Transnational Holdings Ltd, Balkrishna Industries Ltd, Dharmayug Investments Ltd, QRG Investments and Holdings Ltd, Nishant K Agarwal and Mallika Srinivasan, according to a notice filed with the watchdog.

BDR Pharmaceuticals is mainly into four therapeutic segments -- oncology, critical care, gynaecology, and neurology. It is engaged in manufacture and sale of active pharmaceutical ingredients as well as formulations, and contract development and manufacturing services.

In a tweet on Monday, (CCI) said it has approved the "acquisition of minority stake of BDR Pharmaceuticals International Private Limited by Multiples Private Equity Fund III and certain other investors".

Deals beyond a certain threshold require approval from the .

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, April 18 2022. 17:42 IST
RECOMMENDED FOR YOU